Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Recruiting 3Active not recruiting 3Withdrawn 2Unknown 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 5Breast Neoplasms 3Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1MMR-D/MSI-H Colorectal Cancers 1Lymphoma 1Leiomyosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Carboplatin 5niraparib 2Taxes 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Bevacizumab 2talazoparib 1sargramostim 1palbociclib 1oregovomab 1olaparib 1epacadostat 1dostarlimab 1birinapant 1atezolizumab 1aldesleukin 1Specimen Handling 1Sirolimus 1Selenium 1Polymerase Chain Reaction 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Metformin 1Magnetic Resonance Spectroscopy 1Letrozole 1Injections 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Fulvestrant 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Fallopian Tube Neoplasms × niraparib × Clear all
NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

City of Hope Medical Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

AGO Research GmbH

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡